Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
June, 2026
June 2026
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
2930  
Robert Lufkin: Anti-Amyloid Drugs Fail Alzheimer’s Patients
Robert Lufkin/LinkedIn
Apr 30, 2026, 14:09

Robert Lufkin: Anti-Amyloid Drugs Fail Alzheimer’s Patients

Robert Lufkin, Advisor of Metabolic Health and Longevity Expert, shared post on LinkedIn:

“A Cochrane review of 17 trials and 20,342 patients concluded anti-amyloid drugs offer no clinically meaningful benefit for Alzheimer’s.

As a medical school professor, I have watched the amyloid hypothesis dominate Alzheimer’s research for 30 years.

Findings:

  • 17 trials, 20,342 patients
  • Effects on cognitive decline absent or trivial
  • The drugs remove amyloid but raise brain bleeding and swelling risk
  • Authors call for research on other mechanisms

Lead author Dr. Francesco Nonino:

‘These drugs make no meaningful difference to patients.’

This is the textbook story I called out in ‘Lies I Taught in Medical School.’

The amyloid hypothesis was elegant.

As a target, it was wrong.

Growing evidence points to Alzheimer’s as a metabolic disease – driven by insulin resistance, glucose hypometabolism, and mitochondrial dysfunction.

Metabolic dysfunction is the root cause of chronic disease.

Full breakdown coming on the Health Longevity Secrets podcast.

View Cochrane review.”

Robert Lufkin

Stay updated on all scientific advances with Hemostasis Today.

Alzheimer Anti-Amyloid Drugs Cardiometabolic Disease Francesco Nonino Health Hematology Hemophilia Hemostasis Hemostasis News Hemostasis Today Medicine Robert Lufkin
NewsFeed